Moomal Tasneem
A5011738431- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Pediatric Urology and Nephrology Studies
- Genetic and Kidney Cyst Diseases
- Renal and related cancers
Moderna Therapeutics (United States)
2023-2024
Westmead Institute for Medical Research
2018
The University of Sydney
2018
Westmead Hospital
2018
Creative Research Enterprises (United States)
2018
Abstract mRNA-4157 (V940) is an individualized neoantigen therapy targeting up to 34 patient-specific tumor neoantigens induce T-cell responses and potentiate antitumor activity. We report mechanistic insights into the immunogenicity of via characterization from first-in-human, phase 1, KEYNOTE-603 study (NCT03313778) in patients with resected non–small cell lung cancer (Part A: 1-mg mRNA-4157, n = 4) or cutaneous melanoma D: + 200-mg pembrolizumab, 12). Safety, tolerability, were assessed....
<p>Supplementary methods.</p>
<h3>Background</h3> The identification of cancer-specific T cell receptor (TCR) sequences is paramount to the advancement cancer immunotherapies. Recent studies and clinical trials have shown that monoclonal therapy prone immune evasion cells by loss HLA heterozygosity low antigen heterogeneity. Cocktail which comprises TCRs corresponding multiple HLAs antigens has been proposed improve efficacy adoptive transfer therapy. In addition CD8+ cytotoxic cells, neoantigen-specific CD4+ while...
<p>Supplementary Figure 3. Patient responses to individual neoantigens at pre-treatment and post-treatment for patients who received mRNA-4157 monotherapy (A–C) or combination therapy (D–J) using ELISpot assay.</p>
<p>Supplementary Figure 6. mRNA-4157 in combination with pembrolizumab activates an adaptive immune response.</p>
<p>Supplementary Figure 5. Predicted HLA alleles (A) and their associated immunogenic epitopes (B) in patients treated with combination therapy.</p>
<p>Supplementary Figure 4. Predicted HLA alleles (A) and their associated immunogenic epitopes (B) in patients treated with mRNA-4157 monotherapy.</p>
<p>Supplementary Figure 8. Study design for Part A and D.</p>
<div>Abstract<p>mRNA-4157 (V940) is an individualized neoantigen therapy targeting up to 34 patient-specific tumor neoantigens induce T-cell responses and potentiate antitumor activity. We report mechanistic insights into the immunogenicity of mRNA-4157 via characterization from first-in-human, phase 1, KEYNOTE-603 study (NCT03313778) in patients with resected non–small cell lung cancer (Part A: 1-mg mRNA-4157, <i>n</i> = 4) or cutaneous melanoma D: + 200-mg...
<p>Peptide list and HLA types.</p>
<p>Supplementary Figure 2. Characterization of mRNA-4157 neoantigen pool-specific T cells post-expansion at pre-treatment and post-treatment for patients who received monotherapy (A–C) or combination therapy (D–K). (L) Alluvial plot illustrating reactivity.</p>
<p>Supplementary Figure 7. Distribution of T cell subsets pre-treatment and post-treatment for high (Patients 7 6) low 13 14) immune responders.</p>
<p>Supplementary Figure 1. Disease status of patients in the study compared with those broader melanoma populations.</p>